Donor Derived Cell-free DNA & Rejection of Kidney Allografts

See also
Status	Clinical Trial	Phase
Withdrawn	`NCT05811468` - Study Correlation Between Blood, Tissue Gene Expression, Donor Derived Cell Free DNA and Histopathology in Kidney Transplant Recipients
Active, not recruiting	`NCT04078750` - PLATO - Medication Adherence in Transplant Recipients	N/A
Active, not recruiting	`NCT05061303` - Omeprazole and Famotidine in Chronic Dysfunction of the Transplanted Kidney
Recruiting	`NCT06342128` - Molecular Landscape of Microvascular Inflammation in Kidney Allografts

See also

Status

Clinical Trial

Phase

Withdrawn

NCT05811468 - Study Correlation Between Blood, Tissue Gene Expression, Donor Derived Cell Free DNA and Histopathology in Kidney Transplant Recipients

Active, not recruiting

NCT04078750 - PLATO - Medication Adherence in Transplant Recipients

N/A

Active, not recruiting

NCT05061303 - Omeprazole and Famotidine in Chronic Dysfunction of the Transplanted Kidney

Recruiting

NCT06342128 - Molecular Landscape of Microvascular Inflammation in Kidney Allografts

Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.

Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.

Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

NCT number	NCT05995379
Study type	Observational
Source	Paris Translational Research Center for Organ Transplantation
Contact
Status	Completed
Phase
Start date	September 21, 2011
Completion date	August 9, 2022

Donor Derived Cell-free DNA and Rejection of Kidney Allografts

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms